Eintrag weiter verarbeiten
Rate and predictors of non‐response to first‐line antipsychotic treatment in first‐episode schizophrenia
Gespeichert in:
| Zeitschriftentitel: | Human Psychopharmacology: Clinical and Experimental |
|---|---|
| Personen und Körperschaften: | , , , , |
| In: | Human Psychopharmacology: Clinical and Experimental, 30, 2015, 3, S. 173-182 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Chiliza, Bonginkosi Asmal, Laila Kilian, Sanja Phahladira, Lebogang Emsley, Robin Chiliza, Bonginkosi Asmal, Laila Kilian, Sanja Phahladira, Lebogang Emsley, Robin |
|---|---|
| author |
Chiliza, Bonginkosi Asmal, Laila Kilian, Sanja Phahladira, Lebogang Emsley, Robin |
| spellingShingle |
Chiliza, Bonginkosi Asmal, Laila Kilian, Sanja Phahladira, Lebogang Emsley, Robin Human Psychopharmacology: Clinical and Experimental Rate and predictors of non‐response to first‐line antipsychotic treatment in first‐episode schizophrenia Pharmacology (medical) Psychiatry and Mental health Neurology (clinical) Neurology |
| author_sort |
chiliza, bonginkosi |
| spelling |
Chiliza, Bonginkosi Asmal, Laila Kilian, Sanja Phahladira, Lebogang Emsley, Robin 0885-6222 1099-1077 Wiley Pharmacology (medical) Psychiatry and Mental health Neurology (clinical) Neurology http://dx.doi.org/10.1002/hup.2469 <jats:sec><jats:title>Objective</jats:title><jats:p>The goals of this study were to (i) estimate the rate of non‐response to first‐line treatment in first‐episode schizophrenia, (ii) evaluate other outcomes associated with symptom non‐response and (iii) identify demographic, baseline clinical and early treatment response predictors of non‐response.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>This was a single‐site, longitudinal cohort study assessing the effects of treatment with flupenthixol decanoate according to a standardised protocol over 12 months in patients with schizophrenia, schizophreniform and schizo‐affective disorders.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Of 126 patients who received at least one dose of study medication, 84 (67%) completed the study. Fifteen (12%) met our predefined criteria for non‐response. Non‐responders were younger and at baseline had more prominent disorganised symptoms, poorer social and occupational functioning, poorer quality of life for psychological, social and environmental domains, more prominent neurological soft signs (NSS) and lower body mass index. At endpoint, the non‐responders were characterised by higher levels of symptomatology in all domains, poorer functional outcome, poorer quality of life and greater cognitive impairments. They also had more prominent NSS and lower body mass index. The strongest predictors of non‐response were more prominent baseline NSS and poor early (7 weeks) treatment response.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Results are consistent with a lower rate of refractoriness to treatment in first‐episode schizophrenia compared with multi‐episode samples. Copyright © 2015 John Wiley & Sons, Ltd.</jats:p></jats:sec> Rate and predictors of non‐response to first‐line antipsychotic treatment in first‐episode schizophrenia Human Psychopharmacology: Clinical and Experimental |
| doi_str_mv |
10.1002/hup.2469 |
| facet_avail |
Online |
| finc_class_facet |
Chemie und Pharmazie Medizin Psychologie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9odXAuMjQ2OQ |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9odXAuMjQ2OQ |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Rs1 DE-Pl11 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
Wiley, 2015 |
| imprint_str_mv |
Wiley, 2015 |
| issn |
0885-6222 1099-1077 |
| issn_str_mv |
0885-6222 1099-1077 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
chiliza2015rateandpredictorsofnonresponsetofirstlineantipsychotictreatmentinfirstepisodeschizophrenia |
| publishDateSort |
2015 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
Human Psychopharmacology: Clinical and Experimental |
| source_id |
49 |
| title |
Rate and predictors of non‐response to first‐line antipsychotic treatment in first‐episode schizophrenia |
| title_unstemmed |
Rate and predictors of non‐response to first‐line antipsychotic treatment in first‐episode schizophrenia |
| title_full |
Rate and predictors of non‐response to first‐line antipsychotic treatment in first‐episode schizophrenia |
| title_fullStr |
Rate and predictors of non‐response to first‐line antipsychotic treatment in first‐episode schizophrenia |
| title_full_unstemmed |
Rate and predictors of non‐response to first‐line antipsychotic treatment in first‐episode schizophrenia |
| title_short |
Rate and predictors of non‐response to first‐line antipsychotic treatment in first‐episode schizophrenia |
| title_sort |
rate and predictors of non‐response to first‐line antipsychotic treatment in first‐episode schizophrenia |
| topic |
Pharmacology (medical) Psychiatry and Mental health Neurology (clinical) Neurology |
| url |
http://dx.doi.org/10.1002/hup.2469 |
| publishDate |
2015 |
| physical |
173-182 |
| description |
<jats:sec><jats:title>Objective</jats:title><jats:p>The goals of this study were to (i) estimate the rate of non‐response to first‐line treatment in first‐episode schizophrenia, (ii) evaluate other outcomes associated with symptom non‐response and (iii) identify demographic, baseline clinical and early treatment response predictors of non‐response.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>This was a single‐site, longitudinal cohort study assessing the effects of treatment with flupenthixol decanoate according to a standardised protocol over 12 months in patients with schizophrenia, schizophreniform and schizo‐affective disorders.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Of 126 patients who received at least one dose of study medication, 84 (67%) completed the study. Fifteen (12%) met our predefined criteria for non‐response. Non‐responders were younger and at baseline had more prominent disorganised symptoms, poorer social and occupational functioning, poorer quality of life for psychological, social and environmental domains, more prominent neurological soft signs (NSS) and lower body mass index. At endpoint, the non‐responders were characterised by higher levels of symptomatology in all domains, poorer functional outcome, poorer quality of life and greater cognitive impairments. They also had more prominent NSS and lower body mass index. The strongest predictors of non‐response were more prominent baseline NSS and poor early (7 weeks) treatment response.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Results are consistent with a lower rate of refractoriness to treatment in first‐episode schizophrenia compared with multi‐episode samples. Copyright © 2015 John Wiley & Sons, Ltd.</jats:p></jats:sec> |
| container_issue |
3 |
| container_start_page |
173 |
| container_title |
Human Psychopharmacology: Clinical and Experimental |
| container_volume |
30 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792338095932178432 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T15:26:46.424Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Rate+and+predictors+of+non%E2%80%90response+to+first%E2%80%90line+antipsychotic+treatment+in+first%E2%80%90episode+schizophrenia&rft.date=2015-05-01&genre=article&issn=1099-1077&volume=30&issue=3&spage=173&epage=182&pages=173-182&jtitle=Human+Psychopharmacology%3A+Clinical+and+Experimental&atitle=Rate+and+predictors+of+non%E2%80%90response+to+first%E2%80%90line+antipsychotic+treatment+in+first%E2%80%90episode+schizophrenia&aulast=Emsley&aufirst=Robin&rft_id=info%3Adoi%2F10.1002%2Fhup.2469&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792338095932178432 |
| author | Chiliza, Bonginkosi, Asmal, Laila, Kilian, Sanja, Phahladira, Lebogang, Emsley, Robin |
| author_facet | Chiliza, Bonginkosi, Asmal, Laila, Kilian, Sanja, Phahladira, Lebogang, Emsley, Robin, Chiliza, Bonginkosi, Asmal, Laila, Kilian, Sanja, Phahladira, Lebogang, Emsley, Robin |
| author_sort | chiliza, bonginkosi |
| container_issue | 3 |
| container_start_page | 173 |
| container_title | Human Psychopharmacology: Clinical and Experimental |
| container_volume | 30 |
| description | <jats:sec><jats:title>Objective</jats:title><jats:p>The goals of this study were to (i) estimate the rate of non‐response to first‐line treatment in first‐episode schizophrenia, (ii) evaluate other outcomes associated with symptom non‐response and (iii) identify demographic, baseline clinical and early treatment response predictors of non‐response.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>This was a single‐site, longitudinal cohort study assessing the effects of treatment with flupenthixol decanoate according to a standardised protocol over 12 months in patients with schizophrenia, schizophreniform and schizo‐affective disorders.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Of 126 patients who received at least one dose of study medication, 84 (67%) completed the study. Fifteen (12%) met our predefined criteria for non‐response. Non‐responders were younger and at baseline had more prominent disorganised symptoms, poorer social and occupational functioning, poorer quality of life for psychological, social and environmental domains, more prominent neurological soft signs (NSS) and lower body mass index. At endpoint, the non‐responders were characterised by higher levels of symptomatology in all domains, poorer functional outcome, poorer quality of life and greater cognitive impairments. They also had more prominent NSS and lower body mass index. The strongest predictors of non‐response were more prominent baseline NSS and poor early (7 weeks) treatment response.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Results are consistent with a lower rate of refractoriness to treatment in first‐episode schizophrenia compared with multi‐episode samples. Copyright © 2015 John Wiley & Sons, Ltd.</jats:p></jats:sec> |
| doi_str_mv | 10.1002/hup.2469 |
| facet_avail | Online |
| finc_class_facet | Chemie und Pharmazie, Medizin, Psychologie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9odXAuMjQ2OQ |
| imprint | Wiley, 2015 |
| imprint_str_mv | Wiley, 2015 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Rs1, DE-Pl11, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 0885-6222, 1099-1077 |
| issn_str_mv | 0885-6222, 1099-1077 |
| language | English |
| last_indexed | 2024-03-01T15:26:46.424Z |
| match_str | chiliza2015rateandpredictorsofnonresponsetofirstlineantipsychotictreatmentinfirstepisodeschizophrenia |
| mega_collection | Wiley (CrossRef) |
| physical | 173-182 |
| publishDate | 2015 |
| publishDateSort | 2015 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | Human Psychopharmacology: Clinical and Experimental |
| source_id | 49 |
| spelling | Chiliza, Bonginkosi Asmal, Laila Kilian, Sanja Phahladira, Lebogang Emsley, Robin 0885-6222 1099-1077 Wiley Pharmacology (medical) Psychiatry and Mental health Neurology (clinical) Neurology http://dx.doi.org/10.1002/hup.2469 <jats:sec><jats:title>Objective</jats:title><jats:p>The goals of this study were to (i) estimate the rate of non‐response to first‐line treatment in first‐episode schizophrenia, (ii) evaluate other outcomes associated with symptom non‐response and (iii) identify demographic, baseline clinical and early treatment response predictors of non‐response.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>This was a single‐site, longitudinal cohort study assessing the effects of treatment with flupenthixol decanoate according to a standardised protocol over 12 months in patients with schizophrenia, schizophreniform and schizo‐affective disorders.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Of 126 patients who received at least one dose of study medication, 84 (67%) completed the study. Fifteen (12%) met our predefined criteria for non‐response. Non‐responders were younger and at baseline had more prominent disorganised symptoms, poorer social and occupational functioning, poorer quality of life for psychological, social and environmental domains, more prominent neurological soft signs (NSS) and lower body mass index. At endpoint, the non‐responders were characterised by higher levels of symptomatology in all domains, poorer functional outcome, poorer quality of life and greater cognitive impairments. They also had more prominent NSS and lower body mass index. The strongest predictors of non‐response were more prominent baseline NSS and poor early (7 weeks) treatment response.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Results are consistent with a lower rate of refractoriness to treatment in first‐episode schizophrenia compared with multi‐episode samples. Copyright © 2015 John Wiley & Sons, Ltd.</jats:p></jats:sec> Rate and predictors of non‐response to first‐line antipsychotic treatment in first‐episode schizophrenia Human Psychopharmacology: Clinical and Experimental |
| spellingShingle | Chiliza, Bonginkosi, Asmal, Laila, Kilian, Sanja, Phahladira, Lebogang, Emsley, Robin, Human Psychopharmacology: Clinical and Experimental, Rate and predictors of non‐response to first‐line antipsychotic treatment in first‐episode schizophrenia, Pharmacology (medical), Psychiatry and Mental health, Neurology (clinical), Neurology |
| title | Rate and predictors of non‐response to first‐line antipsychotic treatment in first‐episode schizophrenia |
| title_full | Rate and predictors of non‐response to first‐line antipsychotic treatment in first‐episode schizophrenia |
| title_fullStr | Rate and predictors of non‐response to first‐line antipsychotic treatment in first‐episode schizophrenia |
| title_full_unstemmed | Rate and predictors of non‐response to first‐line antipsychotic treatment in first‐episode schizophrenia |
| title_short | Rate and predictors of non‐response to first‐line antipsychotic treatment in first‐episode schizophrenia |
| title_sort | rate and predictors of non‐response to first‐line antipsychotic treatment in first‐episode schizophrenia |
| title_unstemmed | Rate and predictors of non‐response to first‐line antipsychotic treatment in first‐episode schizophrenia |
| topic | Pharmacology (medical), Psychiatry and Mental health, Neurology (clinical), Neurology |
| url | http://dx.doi.org/10.1002/hup.2469 |